Form 144 Krystal Biotech For: 25 February

Krystal Biotech insiders filed a Form 144 with the Securities and Exchange Commission on February 25, 2026, indicating their intention to sell restricted securities, as the biotechnology company's stock dropped 2.80% during the trading session. The filing, which does not represent a binding commitment to sell but rather shows the intent to dispose of shares that were previously restricted, comes amid broader market turbulence in the biotech sector. While the company has not disclosed the specific number of shares or the potential price range, such filings typically provide insight into insider sentiment and can influence investor perception of the company's near-term prospects. Krystal Biotech, known for its gene therapy research, has faced market volatility similar to other biotech firms, with investors weighing the balance between promising research pipelines and the high-risk, high-reward nature of the sector.